Glenmark Pharmaceuticals Ltd. said its US subsidiary Glenmark Generics Inc. had received final abbreviated new drug approvals (ANDA's) from the US FDA for Zolmitriptan tablets in the strengths of 2.5 and 5mg and Zolmitriptan Orally Disintegrating tablets (ODT) in the strengths of 2.5 and 5mg.
The company said it would commence distribution of the product immediately.
Zolmitriptan tablets and Zolmitriptan ODT are Glenmark's generic versions of Zomig and Zomig ZMT by AstraZeneca, indicated for the acute treatment of migraine headaches in adults.
As per IMS Health data, the products garnered sales of $176 million for the twelve months ended December 31, 2012.
At the BSE, Glenmark Pharmaceuticals shares are currently trading at Rs.558.60, up 2.00 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.